Opendata, web and dolomites

MultiDiag

Rapid, cost-effective, multiplex point of care diagnostic immunoassay system

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MultiDiag project word cloud

Explore the words cloud of the MultiDiag project. It provides you a very rough idea of what is the project "MultiDiag" about.

market    disorders    point    infectious    cartridges    laboratory    liquid    sensitive    prepare    elisa    central    15    nalia    lined    incorporated    confirm    first    size    hours    followed    modern    time    provides    earliest    disease    allergy    pricing    patient    care    immunoassays    competition    mainstay    biomarker    reduce    plan    multiplexed    changed    retaining    device    submit    contrast    diagnoses    initial    parallel    oncology    mean    assesses    cartridge    disposable    healthcare    business    diagnosis    decades    diseases    sensitivity    globally    manufacturable    commercial    bench    biomarkers    inherent    laboratories    perform    takes    handling    accurate    feasibility    dramatically    arrays    autoimmune    array    stream    accurately    20min    made    quantification    commercialise    quantitative    route    diagnostic    lt    accuracy    opportunity    whilst    tested    intend    rapid    series    tests    panels    benefits    our    complete    multiplex    clinical    platform    standard    near    data    facilities   

Project "MultiDiag" data sheet

The following table provides information about the project.

Coordinator
NALIA SYSTEMS LIMITED 

Organization address
address: C/O DUBOFF & CO, KINGSBURY HOUSE, 468 CHURCH LANE
city: LONDON
postcode: NW9 8UA
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Project website http://www.naliasystems.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2015
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-07-01   to  2015-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    NALIA SYSTEMS LIMITED UK (LONDON) coordinator 50˙000.00

Map

 Project objective

Our overall project is to develop and prepare to commercialise a rapid, cost-effective platform for near-patient diagnosis using multiplex immunoassays. Development of a cost-effective system for diagnosis by multiplex biomarker analysis at the point-of-care is essential to enable the delivery of modern, stream-lined healthcare systems in the EU and globally that rapidly and accurately assesses patient needs at the earliest opportunity. Immunoassays are a mainstay of clinical diagnoses. ELISA tests provide sensitive, accurate and quantitative diagnostic data for a large number of disease biomarkers. The technology has not changed for decades and requires central laboratory facilities. Each test measures only one biomarker and takes up to 2 hours to perform. NALIA Systems’ technology provides multiplexed ELISA tests in which panels of 10-15 biomarkers can be tested in parallel, whilst retaining the sensitivity, accuracy and quantification benefits of standard ELISA tests. The first NALIA Arrays are now being made available for use in laboratories. Standard ELISA technology cannot be adapted for use at point-of-care due to the time to result and the complex liquid handling needed. In contrast, the inherent characteristics of NALIA’s array technology mean that it can be incorporated into disposable cartridges and dramatically reduce the time to result. This project will develop a bench-top device and disposable cartridge system for biomarker arrays for diagnosis at the point of care. Initial arrays will be for autoimmune disorders, allergy and infectious diseases, followed by oncology and other diseases. In Phase 1 we intend to confirm the feasibility of achieving a result in <20min; to prepare a product development plan that will lead to a manufacturable device and series of cartridges; to complete a business plan covering all aspects of the commercial opportunity, pricing, market size, competition and route to market; and submit an application for Phase 2 funding.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MULTIDIAG" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MULTIDIAG" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

INADVANCE (2019)

Patient-centred pathways of early palliative care, supportive ecosystems and appraisal standard

Read More  

PREFERABLE (2019)

Project on Exercise for Fatigue Eradication in Advanced Breast cancer to improve quality of life

Read More